# A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

> **NCT01955564** · PHASE1 · COMPLETED · sponsor: **Newron Pharmaceuticals SPA** · enrollment: 54 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** NW-3509a

## Key facts

- **NCT ID:** NCT01955564
- **Lead sponsor:** Newron Pharmaceuticals SPA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-09
- **Final completion:** 2015-02
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01955564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01955564, "A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01955564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*